NEW SUPPORT MODALITY UNDP UKRAINE EXPERIENCE ZAFAR YULDASHEV PROJECT COORDINATOR UNDP UKRAINE

Transcription

1 NEW SUPPORT MODALITY UNDP UKRAINE EXPERIENCE ZAFAR YULDASHEV PROJECT COORDINATOR UNDP UKRAINE

2 BACKGROUND The challenges and failures of the Ministry of Health s public procurement and supply programme resulted in a two-year gap of available medicine in the country from May MOH invited agencies to assist with procurement of health products May-Sep 15 UNDP assists in amending local legislation Aug 15 - Internal consultations and meetings with key partners Oct 15 UNDP signs PRODOC and CSA - I with MOH of UKR (7 state programmes) Nov 15 Funds transferred to UNDP Dec 15 CSA II for vaccines signed between UNDP and MOH of UKR (39,2 M USD) NB. Extremely complex political environment, strict regulations, different expectations of parties

3

4 Usual Challenges Stock out situation CHALLENGES Lack of clear requirements Different expectations of the parties CSOs, MOH, Pharm mafia, numerous media attacks, tender complains Short time to implement cases Sabotage at different levels Bid complains to slow the progress of UNDP Usual challenges Credibility of UNDP on the ground

5 PROJECT IMPLEMENTATION New corporate initiative, new approach was needed Consultations with HQ departments/ GF HIST / GPU Procurement Road Map / Ex-ante review (FTP) Bidding processes Tenders Start Finish Notice period Evaluation process finalized TB 7-Dec Dec-15 21d 4-Feb-16 Hemophilia 29-Dec-15 7-Feb-16 41d 8-Mar-16 Vacccines 14-Jan-16 4-Feb-16 22d 22-Feb-16 Hep 4-Feb Feb-16 22d 17-May-16 OD 15-Dec Jan-16 48d 28-Feb-16

6

7 CYCLE II 78 M USD List of programs for procurement with 2016 funds: 1. Medicines and medical products for patients in pre- and posttransplant period 2. Chemotherapeutic agents, radiopharmaceuticals and support drugs for treatment of cancer patients 3. Medicines and medical products for treatment of children with oncology and oncohematology diseases 4. Reagents for neonatal screening for phenylketonuria and congenital hypothyroidism 5. Medicines for treatment of children with cystic fibrosis 6. Medicines for children with primary (congenital) immunodeficiency 7. Medicines for children with cerebral palsy 8. Medicines for children with dwarfism of various origins 9. Medicines for children with mental and behavioral disorders of autism spectrum 10. Medicines for treatment of children with resistant juvenile rheumatoid arthritis 11. Medicines for treatment of patients with mucopolysaccharidosis 12. Medicines and medical products for patients with epidermolysis bullosa 13. Medicines for patients with pulmonary arterial hypertension 14. Anti-D immunoglobulin for the prevention of hemolytic disease of the newborn 15. Medicines and small laboratory equipment for female infertility treatment by means of assisted reproductive technologies 16. Medicines for adults with hemophilia 17. Medicines for treatment of patients with multiple sclerosis 18. Medicines for patients with orphan metabolic diseases 19. Medicines for children with chronical viral hepatitis 20. Tests, supplies for the diagnosis of tuberculosis 21. Medicines for children with hemophilia type A or B or Willebrand disease 22. Medicines for treatment of tuberculosis (TB) 23. Medicines for adults with hemophilia

8 RESULTS & SOURCES PATIENTS WITH HEMOPHILIA WILL RECEIVE HIGH-QUALITY EUROPEAN MEDICINES Oleksandr Shmilo, chairman of the All-Ukrainian Association of Hemophilia: Project web site click here Link to announced ITB "The process and outcome of tenders for hemophilia medicines correspond to European standards. This is the first tender in Ukraine, which was conducted entirely in the interests of patients with hemophilia."

9 LOT Product description Pharmaceutical Presentation Strength Requested QTY Adult Hemophilia 1 Coagulation factor VIII ampule, vial, syringe 1000 IU and more 9,322,713 2 Coagulation factor VIII and von Willebrand factor ampule, vial, syringe 1000 IU and more 5,594,998 3 Coagulation factor IX ampule, vial, syringe 1000 IU and more 3,246,115 4 Eptacog alfa activated (recombinant factor VIIa) ampule, vial, syringe 2 mg (100 KIU or 100,000 IU), 5 mg (250 KIU or 250,000 IU) 10,390,000 5 Anti-inhibitor coagulant complex ampule, vial, syringe 500 IU, 1000 IU 539,500 6 Desmopressin ampule 15μg, 1ml 333 Child hemophilia 7 Coagulation factor VIII (recombinant) vials 250 IU 683,000 8 Coagulation factor VIII (recombinant) vials 500 IU 1,907,600 9 Human coagulation factor VIII (plasma) vials 250 IU 565, Human coagulation factor VIII (plasma) vials 500 IU 7,904, Human coagulation factor IX vials 500 and/or 600 IU 2,469, Human coagulation factor VIII and human von Willebrand factor vials 500 IU 1,293, Human coagulation factor VIII and human von Willebrand factor vials 1000 IU 1,511, Human coagulation factor VIII and human von Willebrand factor vials 500 IU 319, Human coagulation factor VIII and human von Willebrand factor vials 1000 IU 673, Human coagulation factor VIII (plasma) vials 1000 IU 1,595, Eptacog alfa activated (recombinant factor VIIa) vials 2 mg (100 KIU or 100,000 IU) 17,420, Eptacog alfa activated (recombinant factor VIIa) vials 5 mg (250 KIU or 250,000 IU) 24,167, Anti-inhibitor coagulant complex vials 500 IU 240, Anti-inhibitor coagulant complex vials 1000 IU 445, Desmopressin ampule, vials, syringe 15μg, 1ml 227

10 COOPERATION LOCAL PATIENT ORGANIZATIONS UNDP EHC MOU => successful cooperation is ongoing Review of ITB and support in evaluation of received bids UNDP facilitated the meeting with MOH of Ukraine EHC PARTNERS Programme

11 PRIORITIES E-tendering and Sustainable Procurement E-tendering and Sustainable procurement Build the structural and human resource capacity for supply, planning, forecasting, and monitoring and evaluation for transparent and cost-effective procurement at MOH. Assist MOH in establishment of Procurement Agency and gradually hand over procurement function Introduce Digital stock management software Conduct periodic efficiency assessments Encourage local manufacturers to discover world market Support MOH further reform of the national procurement and quality assurance system and capacity development processes.

12 LESSONS LEARNT Carefully consider the local context (requirements, customs, QC, storage, distribution, acceptance by beneficiaries, other regulations) Closely work with MOH to solve the issues at early stages (VAT, Registration of new products, flexibilities with quantities of meds to be purchased etc.) Utilize Bid security and Performance bond tools Collaborate with known Associations in development of bid documents and technical evaluation, reference prices etc.

13 LESSONS LEARNT Collaborate with local patient organizations Involve line experts appointed by MOH as visiting experts Engage MOH into decision making process in each step, ensure ownership Encourage world known manufacturers participation in UNDP tenders Maintain proactive clear and concise Communication Centralization of procurement function Establishment of LTAs